Background
==========

Cardiovascular disease (CVD) is the major factor affecting the prognosis of patients with chronic renal disease (CKD), among whom its morbidity and mortality rates are 10--20 times those in the general population \[[@b1-medscimonit-23-4447]--[@b3-medscimonit-23-4447]\]. Endothelial dysfunction, an intermediate cardiovascular endpoint \[[@b4-medscimonit-23-4447]\], plays a significant role in the development of atherosclerosis and vascular lesions, which were associated with CKD in our previous study.

In addition to traditional CVD risk factors (e.g., hypertension and diabetes) and abnormal renal function, the urine albumin-to-creatinine ratio (UACR) was also shown to be an independent risk factor for cardiovascular disease in non-diabetic and diabetic patients in numerous studies \[[@b5-medscimonit-23-4447]--[@b7-medscimonit-23-4447]\]. However, the mechanisms of the association between albuminuria and CVD are still largely unclear. Little is known about the glomerular filtration rate (GFR)-independent association between endothelial injury, an intermediate step in CVD events, and UACR in CKD patients. We hypothesized that the effect of UACR on the vascular endothelium may be one of the mechanisms leading to CVD in CKD patients. In the present study, we investigated the relationship between UACR and endothelial dysfunction (ED) in CKD patients and the possible mechanism.

Material and Methods
====================

Study design and subjects
-------------------------

This prospective observational study was carried out at the Department of Nephrology, Chinese PLA General Hospital. Between September 2015 and September 2016, consecutive inpatients 18 to 70 years of age with stages 3--5 non-dialysis-dependent CKD were included in this study. To diminish any confounders that may influence patients with endothelial dysfunction, patients were excluded if they: (1) had an established atherosclerotic complication (coronary artery disease, congestive heart failure, or peripheral vascular disease); (2) had a previous diagnosis of diabetes; (3) had a history of chronic dialysis or kidney transplants or had nephrotic syndrome; (4) had a history of use of glucocorticoid or immunosuppressive medication within the last month; and (5) were unwilling to give informed consent. Finally, 151 non-diabetic CKD patients were selected. The etiology of CKD in these patients was chronic glomerulonephritis in 105 and unknown in 46. The research was approved by the Ethics Committee of the General Hospital of the Chinese People's Liberation Army and all subjects signed an informed consent form before participating in the study. A study flowchart is shown in [Figure 1](#f1-medscimonit-23-4447){ref-type="fig"}.

General data collection
-----------------------

The general characteristics \[age, gender, height, weight, systolic blood pressure, and diastolic blood pressure\] and laboratory parameters \[hemoglobin, white blood cell count, platelet count, serum albumin, serum creatinine, cholesterol, triglycerides, interleukin-2, interleukin-6, superoxide dismutase, and UACR\] were determined for all patients.

Body mass index (BMI) and mean arterial pressure (MAP) were calculated as follows: BMI=weight (kg)/\[height (m)\]^2^; MAP=(systolic blood pressure + 2·diastolic blood pressure)/3.

The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was used for the estimated glomerular filtration rate (eGFR)\[[@b8-medscimonit-23-4447]\]. CKD stage was defined in accordance with K/DOQI guidelines \[[@b9-medscimonit-23-4447]\].

Biomarkers of endothelial function
----------------------------------

Specimens of fasting cubital venous blood were collected in the morning. All blood specimens were anticoagulated with 10^9^ mmol/L sodium citrate at a ratio of 9: 1 (blood: citrate). Platelet-poor plasma was obtained from blood specimens by centrifugation at 3000×g for 10 min within 1 h of blood collection. The coagulation factor VIII activity was measured using a coagulation assay. Thrombotic von Willebrand factor (vWF) antigen levels and activity were determined using an immunoturbidimetric assay. The instrument (ACL TOP700) and reagents were all purchased from USA Instrumentation Laboratory Company.

Statistical analysis
--------------------

Data analysis was performed using Statistical Package for Social Science (SPSS) 19 statistical software (Chicago, IL, USA). Results are expressed as the mean ± standard deviation or median (range) for continuous data and as the frequency or percentage for categorical data. We initially compared the baseline characteristics of the study subjects using the t-test, Mann-Whitney U, or chi-squared test, as appropriate. A generalized linear model estimating procedure was used to obtain the adjusted mean levels of procoagulant biomarkers within categories of UACR \[[@b10-medscimonit-23-4447]\]. Interaction between CKD stage (3 levels: CKD3, CKD4, and CKD5) and UACR (2 levels: UACR ≤300 mg/g and UACR \>300 mg/g) was assessed by factorial design analysis of variance (ANOVA). Using multivariable linear regression, we examined the association of eGFR and UACR with markers of endothelial dysfunction. Log transformations were used for biomarkers if they were not normally distributed. The eGFR, UACR, and other baseline characteristics were the independent variables in these analyses, and the hemostatic biomarkers were the dependent variables. P values less than 0.05 were considered statistically significant.

Results
=======

Participant characteristics
---------------------------

According to the definition of microalbuminuria and macroalbuminuria suggested by the American Diabetes Association (2007), we divided the CKD patients into 2 groups: UACR ≤300 mg/g and UACR \>300 mg/g. Baseline information is presented in [Table 1](#t1-medscimonit-23-4447){ref-type="table"}. The patients in the 2 groups showed no significant differences in body mass index, mean arterial pressure, white blood cell count, cholesterol, or triglycerides. Compared with patients with UACR ≤300 mg/g, patients with UACR \>300 mg/g were associated with older age, female sex, and lower hemoglobin, platelet count, serum albumin, eGFR, and superoxide dismutase levels. However, the interleukin-2 and interleukin-6 levels were significantly higher in the UACR \>300 mg/g group. The UACR ≤300 mg/g group had a higher proportion of CKD3 patients, whereas the UACR \>300 mg/g group had a higher proportion of CKD5 patients.

Procoagulant and inflammatory biomarkers according to UACR categories adjusted for baseline covariates
------------------------------------------------------------------------------------------------------

Regardless of adjustment, a higher UACR was associated with increases in vWF: Ag, vWF activity, factor VIII, interleukin-2, and log transformed value of interleukin-6 (log \[interleukin-6\]), as well as a decrease in superoxide dismutase ([Table 2](#t2-medscimonit-23-4447){ref-type="table"}).

Association of eGFR and UACR with endothelial dysfunction
---------------------------------------------------------

When adjusted for demographics, biochemical data, and UACR, for every 10 ml/min/1.73 m^2^ decrease in eGFR, the vWF activity and factor VIII were elevated by 6.4% (95% confidence interval \[95% CI\], 1.0% to 11.8%) and 3.9% (95% CI, 0.7% to 7.2%), respectively. In models adjusted for demographic characteristics, biochemical data, and eGFR, for every 88.5 mg/g (10 mg/mmol) increase in UACR, the vWF activity and factor VIII were elevated by 4.8% (95% CI, 0.9% to 9.4%) and 4.2% (95% CI, 1.0% to 7.3%), respectively ([Table 3](#t3-medscimonit-23-4447){ref-type="table"}).

In addition, the interaction between CKD and UACR with vWF activity, vWF: Ag, and factor VIII is presented in [Figure 2](#f2-medscimonit-23-4447){ref-type="fig"}. There was no significant interaction between these variables (vWF activity: F=0.58, P=0.56; vWF: Ag: F=0.62, P=0.52; factor VIII: F=0.1, P=0.913).

Association of eGFR and UACR with inflammatory biomarkers
---------------------------------------------------------

Additionally, we analyzed the association of kidney function and UACR with inflammatory cytokines by factorial design ANOVA. The results showed that the main effects of the factors UACR and CKD were both statistically significant: the interleukin-2 and log (interleukin-6) levels were significantly higher, while superoxide dismutase was lower in the UACR \>300 mg/g group and in CKD5 patients compared with the UACR ≤300 mg/g group and CKD3 patients, respectively. There was no significant interaction between any 2 factors (interleukin-2: F=0.26, P=0.77; log (interleukin-6): F=0.29, P=0.75; superoxide dismutase: F=0.25, P=0.78) ([Figure 3](#f3-medscimonit-23-4447){ref-type="fig"}).

Discussion
==========

Patients with CKD have endothelial dysfunction, which may contribute to increased risk for cardiovascular events. UACR is an independent risk factor for cardiovascular disease. However, the mechanisms underlying the association between albuminuria and CVD are not fully understood. We hypothesized that the effect of UACR on vascular endothelium may be one of the mechanisms leading to CVD in patients with CKD. Thus, we examined the relationship between UACR and biomarkers of endothelial function in patients with CKD.

In addition to the associations between eGFR and hemostatic markers, a strong correlation between UACR and endothelial dysfunction was confirmed in the present study. CKD patients often present with higher levels of traditional risk factors for thromboembolic events, such as hypertension, diabetes, obesity, and dyslipidemia \[[@b11-medscimonit-23-4447]\], and these factors also affect endothelial function. Before and after adjustment for demographic characteristics and other covariates (e.g., hemoglobin, serum albumin, and blood lipids), the associations between UACR and biomarkers of endothelial dysfunction were attenuated but remained significant. For instance, for every 88.5 mg/g (10 mg/mmol) increase in UACR, the unadjusted vWF activity was elevated by 8.3%, which was attenuated to 4.8% with full adjustment. Moreover, we found no significant interaction between these variables, which indicates that albuminuria does not alter the association between eGFR and endothelial dysfunction.

Extensive basic research has found that inflammation and oxidative stress can induce vascular endothelial cell injury and accelerate atherosclerosis \[[@b12-medscimonit-23-4447],[@b13-medscimonit-23-4447]\]. Additionally, a clinical study demonstrated that inflammation and oxidative stress markers are closely associated with cardiovascular events \[[@b14-medscimonit-23-4447]\]. In the present study, we found that interleukin-2, interleukin-6, and superoxide dismutase had strong correlations with UACR in CKD patients. We infer that these factors may mediate the association between UACR and endothelial dysfunction. Notably, our findings suggest that inflammation and oxidative stress markers change as UACR increases in CKD patients; however, the present study is a cross-sectional study, which only identifies the association between inflammatory cytokines and UACR but does not demonstrate a causal relationship between inflammatory cytokines, UACR, and endothelial injury. For example, increased inflammation could have caused both UACR and endothelial dysfunction \[[@b4-medscimonit-23-4447],[@b15-medscimonit-23-4447]\]. Additionally, albuminuria can alter the levels of inflammatory cytokines and thrombotic cascades \[[@b16-medscimonit-23-4447]\] and can contribute to CVD.

The present study has certain limitations. First, the vascular endothelium has multiple physiological functions, such as regulating vascular tension, resisting coagulation, and promoting fibrinolysis, in addition to its participation in the inflammatory response. In addition to the serological marker vWF, other indicators, such as reactive hyperemia peripheral arterial tonometry (RH-PAT), should be tested; these indicators can better reflect the physiological functions of the vascular endothelium. However, further investigation was not carried out because such test methods are not yet available at our center. Second, this was a cross-sectional study, and there was no further follow-up after the endpoint of cardiovascular events. We could not establish a relationship between endothelial dysfunction and eventual subsequent thromboembolic events in CKD patients.

Conclusions
===========

This study demonstrates that a higher UACR is GFR-independently associated with elevations in markers of endothelial function and inflammatory factors in CKD patients. These findings suggest that therapies aimed at treating albuminuria may help to alleviate endothelial dysfunction.

**Source of support:** This work was supported by the National Sciences Foundation of China \[grant numbers 81273968, 81471027, and 81072914\]; Ministerial projects of the National Working Commission on Aging \[grant number QLB2014W002\]; and The Four Hundred project of 301 \[grant number YS201408\]
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###### 

Baseline characteristics of the study cohort.

  Variables                          CKD patients (n=151)                                             Urine albumin-to-creatinine ratio ≤300 mg/g (n=79)                                                                  Urine albumin-to-creatinine ratio \>300 mg/g (n=72)              P
  ---------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ---------
  Gender, M, n (%)                   95 (63%)[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}     58 (73%)[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}                                                        37 (51%)[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}     0.013
  Age (year)                         43.6±12.9                                                        41.6±12.6                                                                                                           45.9±13.0                                                        0.121
  Body mass index (kg/m^2^)          24.6±3.7                                                         24.2±3.3                                                                                                            24.9±4.1                                                         0.475
  Mean arterial pressure (mmHg)      98.1±11.6                                                        96.6±13.2                                                                                                           99.7±9.2                                                         0.264
  Hemoglobin (g/L)                   118.5±21.5[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}   124.2±22.0[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}                                                      112.3±19.3[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}   0.003
  Platelet count (10^9^/l)           212.2±57.3                                                       203.5±51.2                                                                                                          221.8±62.4                                                       0.147
  White blood cell count (10^9^/l)   7.1±1.9                                                          7.0±1.7                                                                                                             7.3±2.1                                                          0.747
  Serum albumin (g/L)                39.9±4.0[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}     40.9±3.5[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}                                                        38.7±4.1[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}     0.004
  eGFR (ml/min/1.73 m^2^)            30.9±17.7[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}    36.7±19.6[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}   24.4±12.6[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}    \<0.001
  CKD3 stage, N (%)                  58 (38%)[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}     43 (54%)[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}    15 (21%)[\*](#tfn2-medscimonit-23-4447){ref-type="table-fn"}     \<0.001
  CKD4 stage, N (%)                  55 (36%)                                                         23 (29%)                                                                                                            32 (44%)                                                         0.148
  CKD5 stage, N (%)                  38 (25%)                                                         13 (16%)[\#](#tfn3-medscimonit-23-4447){ref-type="table-fn"}                                                        25 (35%)                                                         0.036
  Cholesterol (mmol/l)               4.2±0.9                                                          4.0±1.0                                                                                                             4.3±0.8                                                          0.161
  Triglycerides (mmol/l)             2.0±0.9                                                          2.0±0.9                                                                                                             2.0±0.9                                                          0.999

Data are expressed as mean ± standard deviation (SD) or median (interquatile range) as appropriate; eGFR -- estimated glomerular filtration rate; CKD -- chronic kidney disease.

P\<0.05, *vs.* CKD group;

P\<0.05, *vs.* UACR \>300 mg/g group.

###### 

Unadjusted and adjusted levels of procoagulant and inflammatory biomarkers.

  Variables           Unadjusted    P             Multivariable-adjusted[\*](#tfn5-medscimonit-23-4447){ref-type="table-fn"}   P                           
  ------------------- ------------- ------------- ---------------------------------------------------------------------------- ------------- ------------- ---------
  VWF: Ag (%)         140.2±51.7    181.7±45.7    \<0.001                                                                      145.1±49.2    177.9±49.7    \<0.001
  VWF: activity (%)   131.2±49.2    176.9±47.9    \<0.001                                                                      135.4±49.2    173.6±49.7    \<0.001
  Factor VIII (%)     120.6±29.7    142.5±23.7    \<0.001                                                                      124.3±25.2    137.6±25.6    0.030
  IL-2 (U/ml)         728.5±201.7   880.2±233.4   0.004                                                                        748.3±172.2   859.5±180.0   0.044
  Log(IL-6 (pg/ml))   0.53±0.3      0.78±0.3      \<0.001                                                                      0.57±0.3      0.75±0.3      0.007
  SOD (U/ml)          151.7±21.5    135.1±14.7    0.001                                                                        148.1±14.7    138.8±15.3    0.036

IL -- Interleukin; SOD -- Superoxide dismutase.

Adjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and eGFR.

###### 

Association of eGFR and UACR with endothelial dysfunction: difference in hemostatic marker per 10 ml/min/1.73 m^2^ decrease in eGFR and per 88.5-U increase of UACR.

  Cohort and variables          Unadjusted changes (95% CI)[\*](#tfn6-medscimonit-23-4447){ref-type="table-fn"}   P         Adjusted changes (95% CI)                                             P
  ----------------------------- --------------------------------------------------------------------------------- --------- --------------------------------------------------------------------- -------
  vWF activity (%)                                                                                                                                                                                
   UACR, mg/g                   8.3 (4.1, 12.5)                                                                   \<0.001   4.8 (0.9, 9.4)[&](#tfn8-medscimonit-23-4447){ref-type="table-fn"}     0.040
   eGFR, ml/min per 1.73 m^2^   11.0 (6.2, 15.8)                                                                  \<0.001   6.4 (1.0, 11.8)[\#](#tfn7-medscimonit-23-4447){ref-type="table-fn"}   0.020
  Factor VIII (%)                                                                                                                                                                                 
   UACR, mg/g                   6.3 (3.1, 9.5)                                                                    \<0.001   4.2 (1.0, 7.3)[&](#tfn8-medscimonit-23-4447){ref-type="table-fn"}     0.011
   eGFR, ml/min per 1.73 m^2^   6.6 (3.4, 9.8)                                                                    0.017     3.9 (0.7, 7.2)[\#](#tfn7-medscimonit-23-4447){ref-type="table-fn"}    0.018

Reported for a 10-U decrease of eGFR or 88.5-U increase of UACR. For UACR, to convert from milligrams per gram to milligrams per millimole, multiply by 0.113;

bAdjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and UACR;

Adjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and eGFR.
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